Hana Biosciences, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Hana Biosciences, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Hana Biosciences, Inc.. The Group's principle activity is to acquire, develop and commercialize of innovative biopharmaceutical products to advance cancer care. It has four product candidates in various stages of development: Marqibo being developed for the treatment of adult acute lymphoblastic leukemia (ALL) and metastatic uveal melanoma. Menadione, a novel supportive care product candidate being developed for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors (EGFRI), a type of anti-cancer agent used in the treatment of certain cancers. Brakiva developed for the treatment of solid tumors including small cell lung cancer and ovarian cancer. Alocrest developed for the treatment of solid tumors such as non-small-cell lung cancer (NSCLC).

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report